Oritavancin for the Treatment of Staphylococcus aureus Bacteremia—A Retrospective Single-arm Cohort Study - Top-Institutions - MDSpire

Oritavancin for the Treatment of Staphylococcus aureus Bacteremia—A Retrospective Single-arm Cohort Study

  • By

  • H Jordan

  • K Kozierowski

  • R Pickles

  • J S Davis

  • June 12, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Microbiology

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Pharmacoeconomics

  • #3

    University of California, San Francisco Medical Center
    University of California, San Francisco Medical Center

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Clinical Trials
    • Pharmacology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Infectious Diseases
    • Clinical Research
    • Health Economics

  • #5

    University of Sydney, Hunter New England Local Health District
    University of Sydney, Hunter New England Local Health District

    Newcastle, NSW, Australia

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Public Health

Original Source(s)

Oritavancin for the Treatment of Staphylococcus aureus Bacteremia—A Retrospective Single-arm Cohort Study

  • by H Jordan, K Kozierowski, R Pickles, J S Davis

  • June 12, 2025

Related Content

Staphylococcus aureus small colony variants originating from the lower respiratory tract are associated with persistent pulmonary infection

Zone-specific hepatocytes orchestrate the early onset of host immune defenses during Staphylococcus aureus bloodstream infection

Dalbavancin Exposure Linked to Higher Success in Bacteremia

Higher day 22 concentrations were associated with improved outcomes, though findings remain exploratory